JP2016518341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518341A5 JP2016518341A5 JP2016503301A JP2016503301A JP2016518341A5 JP 2016518341 A5 JP2016518341 A5 JP 2016518341A5 JP 2016503301 A JP2016503301 A JP 2016503301A JP 2016503301 A JP2016503301 A JP 2016503301A JP 2016518341 A5 JP2016518341 A5 JP 2016518341A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- item
- label
- fluorescent label
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 239000007850 fluorescent dye Substances 0.000 claims description 18
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 14
- -1 bora-diaza-indecene Chemical compound 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 102000005600 Cathepsins Human genes 0.000 claims description 2
- 108010084457 Cathepsins Proteins 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794296P | 2013-03-15 | 2013-03-15 | |
| US61/794,296 | 2013-03-15 | ||
| PCT/US2014/029990 WO2014145257A2 (en) | 2013-03-15 | 2014-03-15 | Activity-based probe compounds, compositions, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034163A Division JP2019081791A (ja) | 2013-03-15 | 2019-02-27 | 活性に基づくプローブの化合物、組成物、および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518341A JP2016518341A (ja) | 2016-06-23 |
| JP2016518341A5 true JP2016518341A5 (enExample) | 2017-04-20 |
| JP6490660B2 JP6490660B2 (ja) | 2019-03-27 |
Family
ID=51538442
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503301A Active JP6490660B2 (ja) | 2013-03-15 | 2014-03-15 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2019034163A Withdrawn JP2019081791A (ja) | 2013-03-15 | 2019-02-27 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2021005558A Withdrawn JP2021059606A (ja) | 2013-03-15 | 2021-01-18 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2023060174A Active JP7689753B2 (ja) | 2013-03-15 | 2023-04-03 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2025084936A Pending JP2025124721A (ja) | 2013-03-15 | 2025-05-21 | 活性に基づくプローブの化合物、組成物、および使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034163A Withdrawn JP2019081791A (ja) | 2013-03-15 | 2019-02-27 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2021005558A Withdrawn JP2021059606A (ja) | 2013-03-15 | 2021-01-18 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2023060174A Active JP7689753B2 (ja) | 2013-03-15 | 2023-04-03 | 活性に基づくプローブの化合物、組成物、および使用方法 |
| JP2025084936A Pending JP2025124721A (ja) | 2013-03-15 | 2025-05-21 | 活性に基づくプローブの化合物、組成物、および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10100037B2 (enExample) |
| EP (2) | EP2971065B1 (enExample) |
| JP (5) | JP6490660B2 (enExample) |
| KR (1) | KR102279618B1 (enExample) |
| CN (2) | CN105431546A (enExample) |
| ES (1) | ES2938225T3 (enExample) |
| WO (1) | WO2014145257A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014145257A2 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
| CA2963305A1 (en) | 2014-10-06 | 2016-04-14 | Cortexyme, Inc. | Inhibitors of lysine gingipain |
| CN107406872B (zh) | 2015-01-22 | 2023-03-28 | 里兰斯坦福初级大学理事会 | 用于标记动物组织的化合物、组合物及其应用 |
| CA3004095A1 (en) | 2015-11-09 | 2017-05-18 | Cortexyme, Inc. | Inhibitors of arginine gingipain |
| CA3036862A1 (en) | 2016-09-16 | 2018-03-22 | Cortexyme, Inc. | Ketone inhibitors of lysine gingipain |
| EP3526232A4 (en) * | 2016-10-11 | 2019-11-20 | The Regents of the University of California | DETECTION, IDENTIFICATION AND CLEANING OF REMOVABLE AND NON-DEGRADABLE ENZYMES IN BIOLOGICAL SAMPLES |
| EP3510380B1 (en) | 2016-12-23 | 2023-11-08 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
| EP3601261A4 (en) | 2017-03-30 | 2021-07-14 | The Board of Trustees of the Leland Stanford Junior University | CONTRAST AGENTS ACTIVATED BY A PROTEASE FOR IN VIVO IMAGING |
| US11635436B2 (en) | 2017-04-24 | 2023-04-25 | Georgetown University | Compositions and methods for analyzing cysteine |
| CA3119793A1 (en) * | 2017-11-28 | 2019-08-01 | Board Of Regents Of The University Of Nebraska | Radiopharmaceuticals and methods of use thereof |
| US12486293B2 (en) | 2018-07-30 | 2025-12-02 | Georgetown University | Chirality sensing with molecular click chemistry probes |
| US11860084B2 (en) | 2018-09-11 | 2024-01-02 | Georgetown University | Quantitative auxiliary-free chirality sensing with a metal probe |
| JP2022515112A (ja) * | 2018-12-20 | 2022-02-17 | 武田薬品工業株式会社 | システインプロテアーゼのためのプローブとしてのスルホキソニウムイリド誘導体 |
| BR112021012036A2 (pt) * | 2018-12-20 | 2021-09-21 | Takeda Pharmaceutical Company Limited | Novas sondas baseadas em atividade para elastase neutrofílica e seu uso |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5055451A (en) * | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| AU2704395A (en) * | 1995-06-13 | 1997-01-09 | Sanofi Winthrop, Inc. | Calpain inhibitors for the treatment of neurodegenerative di seases |
| US5989823A (en) | 1998-09-18 | 1999-11-23 | Nexstar Pharmaceuticals, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
| JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（−）−ビュープロピオンの薬学的使用 |
| US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| CA2335359C (en) | 1999-04-23 | 2007-07-17 | Molecular Probes, Inc. | Xanthene dyes and their application as luminescence quenching compounds |
| US7019129B1 (en) | 2000-05-09 | 2006-03-28 | Biosearch Technologies, Inc. | Dark quenchers for donor-acceptor energy transfer |
| US20020052323A1 (en) * | 2000-08-30 | 2002-05-02 | Jinhai Wang | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents |
| GB0112868D0 (en) | 2001-05-25 | 2001-07-18 | Secr Defence | Detection system |
| US20050014160A1 (en) | 2003-07-18 | 2005-01-20 | Sriram Kumaraswamy | Assays for protease enzyme activity |
| US8968700B2 (en) | 2005-08-11 | 2015-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging of protease activity in live cells using activity based probes |
| WO2009124265A1 (en) * | 2008-04-03 | 2009-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Probes for in vivo targeting of active cysteine proteases |
| WO2012021800A2 (en) * | 2010-08-13 | 2012-02-16 | Banyan Biomarkers | Caspase inhibitors as therapeutics for neural and organ injury and imaging |
| WO2012118715A2 (en) * | 2011-02-28 | 2012-09-07 | The Board Of Trustees Of Leland Stanford Junior University | Non-peptidic quenched fluorescent imaging probes |
| KR20160037834A (ko) | 2013-03-14 | 2016-04-06 | 루미셀, 아이엔씨. | 의료 이미징 장치 및 사용 방법 |
| WO2014145257A2 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
| EP3510380B1 (en) * | 2016-12-23 | 2023-11-08 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
-
2014
- 2014-03-15 WO PCT/US2014/029990 patent/WO2014145257A2/en not_active Ceased
- 2014-03-15 EP EP14764975.0A patent/EP2971065B1/en active Active
- 2014-03-15 KR KR1020157029213A patent/KR102279618B1/ko active Active
- 2014-03-15 EP EP22213062.7A patent/EP4218829A3/en active Pending
- 2014-03-15 CN CN201480028287.7A patent/CN105431546A/zh active Pending
- 2014-03-15 JP JP2016503301A patent/JP6490660B2/ja active Active
- 2014-03-15 ES ES14764975T patent/ES2938225T3/es active Active
- 2014-03-15 US US14/777,024 patent/US10100037B2/en active Active
- 2014-03-15 CN CN202510298059.1A patent/CN120132004A/zh active Pending
-
2018
- 2018-10-02 US US16/150,167 patent/US10829477B2/en active Active
-
2019
- 2019-02-27 JP JP2019034163A patent/JP2019081791A/ja not_active Withdrawn
-
2020
- 2020-11-09 US US17/092,587 patent/US11655236B2/en active Active
-
2021
- 2021-01-18 JP JP2021005558A patent/JP2021059606A/ja not_active Withdrawn
-
2023
- 2023-04-03 JP JP2023060174A patent/JP7689753B2/ja active Active
- 2023-05-22 US US18/321,684 patent/US20230391750A1/en active Pending
-
2025
- 2025-05-21 JP JP2025084936A patent/JP2025124721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518341A5 (enExample) | ||
| Nogales et al. | A novel fluorescent and bioluminescent bireporter influenza A virus to evaluate viral infections | |
| JP2018511556A5 (enExample) | ||
| ES2696074T3 (es) | Tratamiento del cáncer de mama | |
| JP2017536344A5 (enExample) | ||
| JP2018504379A5 (enExample) | ||
| JP2012506703A5 (enExample) | ||
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| MY171854A (en) | Wt1 antigen peptide conjugate vaccine | |
| JP2018507197A5 (enExample) | ||
| EP4541378A3 (en) | Compounds for positron emission tomography | |
| JP2012518029A5 (enExample) | ||
| NO20092274L (no) | Ansamycinformuleringer og fremgangsmater for anvendelse derav | |
| JP2014177455A5 (enExample) | ||
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| FI3246070T3 (fi) | Uusia fxr:ää (nr1h4) sitovia ja aktiivisuutta muokkaavia atsoleja | |
| JP2017526753A5 (enExample) | ||
| JP2018509143A5 (enExample) | ||
| JP2010527913A5 (enExample) | ||
| MX385488B (es) | Lipido cationico. | |
| JP2017533886A5 (enExample) | ||
| EP4310504A3 (en) | Activity-based probe compounds, compositions, and methods of use | |
| JP2020513050A5 (enExample) | ||
| UY34916A (es) | "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético" | |
| JP2013518032A5 (enExample) |